Masonic Cancer Center, University Of Minnesota
Clinical trials sponsored by Masonic Cancer Center, University Of Minnesota, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune booster may strengthen stem cell transplant against hodgkin lymphoma Results expected Sep 2026 (estimated)
- Unlicensed cord blood units tested for safety in blood cancer patients Results expected Sep 2026 (estimated)
- New stem cell approach aims to beat lymphoma without radiation Results expected Sep 2026 (estimated)
- Double-Dose stem cell therapy shows promise for tough childhood cancer Results expected Oct 2026 (estimated)
- Can exercise tests reveal hidden health clues in childhood disease survivors? Results expected Nov 2026 (estimated)
-
Cord blood transplant trial for blood cancers halted early
Disease control Stopped earlyThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo aims to tame deadly transplant complication with fewer steroids
Disease control Stopped earlyThis study tested a combination of three drugs (ruxolitinib, uhCG/EGF, and steroids) in 10 people with a severe form of acute graft-versus-host disease (aGVHD), a complication that can occur after a stem cell transplant. The goal was to find the lowest effective steroid dose to r…
Phase 1/2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC